Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
ENTPD5
Introduction
Ectonucleoside triphosphate diphosphohydrolase 5 is an enzyme that in humans is encoded by the ENTPD5 gene.[1][2][3]
ENTPD5 is similar to E-type nucleotidases (NTPases)/ecto-ATPase/apyrases. NTPases, such as CD39, mediate catabolism of extracellular nucleotides. ENTPD5 contains 4 apyrase-conserved regions which is characteristic of NTPases.[3]
References
References
- ↑ Chadwick BP, Frischauf AM (Oct 1997). “Cloning and mapping of a human and mouse gene with homology to ecto-ATPase genes”. Mamm Genome. 8 (9): 668–72. doi:10.1007/s003359900534. PMID 9271669.
- ↑ Chadwick BP, Frischauf AM (Oct 1998). “The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster”. Genomics. 50 (3): 357–67. doi:10.1006/geno.1998.5317. PMID 9676430.
- ↑ 3.0 3.1 “Entrez Gene: ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5”.
Further reading
Further reading
- Mulero JJ, Yeung G, Nelken ST, Ford JE (1999). “CD39-L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates”. J. Biol. Chem. 274 (29): 20064–7. doi:10.1074/jbc.274.29.20064. PMID 10400613.
- Recio JA, Zambrano N, Peña L, et al. (2000). “The human PCPH proto-oncogene: cDNA identification, primary structure, chromosomal mapping, and expression in normal and tumor cells”. Mol. Carcinog. 27 (3): 229–36. doi:10.1002/(SICI)1098-2744(200003)27:3<229::AID-MC10>3.0.CO;2-Z. PMID 10708485.
- Mulero JJ, Yeung G, Nelken ST, et al. (2000). “Biochemical characterization of CD39L4”. Biochemistry. 39 (42): 12924–8. doi:10.1021/bi000960y. PMID 11041857.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Blánquez MJ, Regadera J, Mariño J, et al. (2003). “Gradual deregulation and loss of PCPH expression in the progression of human laryngeal neoplasia”. Mol. Carcinog. 35 (4): 186–95. doi:10.1002/mc.10091. PMID 12489110.
- Murphy-Piedmonte DM, Crawford PA, Kirley TL (2005). “Bacterial expression, folding, purification and characterization of soluble NTPDase5 (CD39L4) ecto-nucleotidase”. Biochim. Biophys. Acta. 1747 (2): 251–9. doi:10.1016/j.bbapap.2004.11.017. PMID 15698960.
- Liu T, Qian WJ, Gritsenko MA, et al. (2006). “Human Plasma N-Glycoproteome Analysis by Immunoaffinity Subtraction, Hydrazide Chemistry, and Mass Spectrometry”. J. Proteome Res. 4 (6): 2070–80. doi:10.1021/pr0502065. PMC 1850943. PMID 16335952.
- Regadera J, Blánquez MJ, González-Peramato P, et al. (2006). “PCPH expression is an early event in the development of testicular germ cell tumors”. Int. J. Oncol. 28 (3): 595–604. doi:10.3892/ijo.28.3.595. PMID 16465363.
- Villar J, Arenas MI, MacCarthy CM, et al. (2007). “PCPH/ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a protein kinase C delta-dependent mechanism”. Cancer Res. 67 (22): 10859–68. doi:10.1158/0008-5472.CAN-07-2041. PMID 18006831.